The efficacy of traditional Chinese medicine in the treatment of new coronary pneumonia has been recognized by the WHO expert meeting. According to The Paper, the report of the “World Health Organization Expert Evaluation Meeting on the Treatment of New Coronary Pneumonia with Traditional Chinese Medicine” was released on the WHO official website on March 31. 21 international experts from 6 WHO regions participated in the evaluation meeting. The meeting report stated:Traditional Chinese medicine can effectively treat new coronary pneumonia, reduce the conversion of mild and common cases to severe cases, shorten the virus clearance time, and improve the clinical prognosis of mild and common patients.
access:
Alibaba Cloud’s “Shadowless Cloud Computer” supports enterprises to quickly realize home office
According to the United Nations official WeChat news, the report pointed out that according to the relevant data results,The Chinese medicines included in the study are beneficial for the treatment of new coronary pneumonia, especially for mild and common cases; Chinese medicines are beneficial for reducing the conversion of mild and common cases to severe cases;
For mild and common cases, compared with conventional treatment alone, the inclusion of traditional Chinese medicine as an additional interventionwhich can shorten virus clearance time, clinical symptom relief time and hospital stay;
At the same time, there is evidence that the early use of traditional Chinese medicine can lead to better clinical prognosis in mild and ordinary patients.
Experts at the meeting made recommendations to WHO, including: encouraging member states to consider integrating traditional medicine interventions, such as traditional Chinese medicine, into the clinical management of COVID-19 in their health systems and regulatory frameworks;
Member States are encouraged to consider the integrative medicine model (integrated Chinese and Western medicine) that has been developed and applied in China; and to advance international clinical trials to further evaluate the potential benefits and safety of Chinese medicine in the treatment of COVID-19 patients throughout the care process.
